PW, I’ve learned a lot about ACT. I have no doubt that the Wolchok Lab is saying in #1651 that the effectiveness either type (the latest of Adoptive TCell Transfer (ACT), be it TCRs or CAR T (ie, the newer gene-modified T cells approaches), is improved by combining with Bavi, and makes for a “highly desirable strategy.”
Good post, CJ, thanks.
At the ASM, 3 years ago, I think, SK told me that a big problem with the immunotherapies was that at the doses being given there was too much danger of a cytokine(?) response with severe, possibly deadly, results. He opined that adding Bavi to the cocktail might enable lower doses of the PD-1 et al to be effective w/o triggering the undesired response. It seems the ACT's that you're discussing will also benefit from Bavi.
Best!
RCJ
News 
Market Data 
Discover 
